Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| MAGI'S LAB - |
RCV000664327 | SCV000599452 | likely pathogenic | Vitelliform macular dystrophy 2 | 2017-09-11 | criteria provided, single submitter | clinical testing | The variation c.26T>G, p.(Val9Gly) found in a patient affected by Best vitelliform macular dystrophy (BVMD) is located in a mutational hot spot, i.e. is a novel missense change at an amino acid residue where different missense changes such as p.(Val9Ala) (Petrukhin et al., 1998; Ponjavic et al., 1999), p.(Val9Met) (Marquardt et al., 1998), p.(Val9Glu) (Maia-Lopes et al., 2008) and p.(Val9Leu) (Kinnick et al., 2011) variants have been associated with BVMD before. Application of ACMG guidelines: PM1 Located in a mutational hot spot and/or critical and well-established functional domain (e.g., active site of an enzyme) without benign variation PM2 Absent from controls (or at extremely low frequency if recessive) (table 6) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium PM5 Novel missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before Example: Arg156His is pathogenic; now you observe Arg156Cys PP2 Missense variant in a gene that has a low rate of benign missense variation and in which missense variants are a common mechanism of disease PP3 Multiple lines of computational evidence support a deleterious effect on the gene or gene product (conservation, evolutionary, splicing impact, etc.) PP4 Patient’s phenotype or family history is highly specific for a disease with a single genetic etiology Likely pathogenic >=3 Moderate (PM1-PM6) OR 2 Moderate (PM1-PM6) AND >= 2 supporting (PP1-PP5) |